PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: A meta-analysis of case-control studies

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 4011-4016

  De Cosmo, Salvatore ^a   Prudente, Sabrina ^b   Lamacchia, Olga ^c   Lapice, Emanuela ^d   Morini, Eleonora ^a,b   Di Paola, Rosa ^b   Copetti, Massimiliano ^b   Ruggenenti, Piero ^e,f   Remuzzi, Giuseppe ^e,f   Vaccaro, Olga ^d   Cignarelli, Mauro ^c   Trischitta, Vincenzo ^b,g  

^a Unit of Endocrinology   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

genetics of diabetic nephropathy; insulin resistance; meta analysis

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; ALBUMINURIA; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PPARGAMMA2 GENE; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; URINALYSIS; URINARY EXCRETION;

ALBUMINURIA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 82255181476     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr187     Document Type: Article

References (40)

1. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432 (Pubitemid 12123979)
2. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997 (Pubitemid 29379934)
3. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
4. Langefeld CD, Beck SR, Bowden DW et al. Heritability of GFR and albuminuria in Caucasians with Type 2 diabetes mellitus. Am J Kidney Dis 2004; 5: 796-800 (Pubitemid 38529616)
5. Placha G, Canani LH, Warram JH et al. Evidence for different susceptibility genes for proteinuria and ESRD in Type 2 Diabetes. Adv Chronic Kidney Dis 2005; 12: 155-169 (Pubitemid 40488998)
6. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800 (Pubitemid 28201810)
7. De Cosmo S, Minenna A, Ludovico O et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care 2005; 28: 910-915 (Pubitemid 40434494)
8. Parvanova AI, Trevisan R, Iliev IP et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006; 55: 1456-1462 (Pubitemid 44195387)
9. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab 2008; 8: 186-200
10. Ridderstråle M, Groop L. Genetic dissection of type 2 diabetes. Mol Cell Endocrinol 2009; 297: 10-17
11. Florez JC. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 2008; 93: 4633-4642
12. Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol 2009; 5: 682-693
13. Tonjes A, Scholz M, Loeffler M et al. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: metaanalysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29: 2489-2497 (Pubitemid 44912258)
14. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80
15. Ludovico O, Pellegrini F, Di Paola R et al. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity 2007; 5: 1076-1081 (Pubitemid 46932461)
16. Gouda HN, Sagoo GS, Harding A-H et al. The Association Between the Peroxisome Proliferator-Activated Receptor-g2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: a HuGE Review and Meta-Analysis. Am J Epidemiol 2010; 171: 645-655
17. Herrmann SM, Ringel J, Wang JG et al. Peroxisome proliferatoractivated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002; 51: 2653-2657 (Pubitemid 34827420)
18. Caramori ML, Canani LH, Costa LA et al. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003; 52: 3010-3013 (Pubitemid 37466874)
19. Pollex RL, Mamakeesick M, Zinman B et al. Peroxisome proliferatoractivated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 2007; 21: 166-171 (Pubitemid 46687068)
20. De Cosmo S, Motterlini N, Prudente S et al. Impact of the PPARgamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009; 58: 2920-2929
21. Liu L, Zheng T, Wang F et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010; 33: 144-149
22. Lapice E, Pinelli M, Riccardi G et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 2010; 33: e114
23. Mori H, Ikegami H, Kawaguchi Y et al. The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50: 891-894 (Pubitemid 32242650)
24. De Cosmo S, Lamacchia O, Rauseo A et al. Cigarette smoking is associated with low glomerular filtration rate in male patients with type 2 diabetes. Diabetes Care 2006; 29: 2467-2470 (Pubitemid 44912254)
25. Gatling W, Knight C, Mullee MA et al. Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabet Med 1988; 5: 343-347
26. Baratta R, Di Paola R, Spampinato D et al. Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARc2 (P12A) polymorphisms. J Mol Med 2003; 81: 718-723 (Pubitemid 37491597)
27. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560 (Pubitemid 37088507)
28. Egger M, Davey SG, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634 (Pubitemid 27387172)
29. Duval S, Tweedie R. Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463 (Pubitemid 30422636)
30. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624 (Pubitemid 34141379)
31. Morini E, Tassi V, Capponi D et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity 2008; 16: 1467-1470 (Pubitemid 351770520)
32. Florez JC, Jablonski KA, SunMWet al. Effects of the type 2 diabetesassociated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92: 1502-1509 (Pubitemid 46556431)
33. Zeggini E, Parkinson JRC, Halford S et al. Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetesrelated traits in UK samples. Diabet Med 2005; 22: 1696-1700 (Pubitemid 43046470)
34. De Cosmo S, Minenna A, Zhang YY et al. Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. Am J Kidney Dis 2009; 53: 273-280
35. De Cosmo S, Prudente S, Andreozzi F et al. Glutamine to arginine substitution at amino acid 84 of mammalian tribbles homolog TRIB3 and CKD in whites with type 2 diabetes. Am J Kidney Dis 2007; 50: 688-689 (Pubitemid 47444456)
36. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
37. Sarafidis PA, Stafylas PC, Georgianos PI et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010; 55: 835-847
38. Kang ES, Park SY, Kim HJ et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor c2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 75: 202-208
39. Wolford JK, Yeatts KA, Dhanjal SK et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005; 54: 3319-3325 (Pubitemid 43334389)
40. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-c2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26: 825-831 (Pubitemid 36929350)